Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus

Abstract Background Atypical teratoid/rhabdoid tumors (ATRTs) are known to exhibit molecular and clinical heterogeneity even though SMARCB1 inactivation is the sole recurrent genetic event present in nearly all cases. Indeed, recent studies demonstrated 3 molecular subgroups of ATRTs that are genetically, epigenetically, and clinically distinct. As these studies included different numbers of tumors, various subgrouping techniques, and naming, an international working group sought to align previous findings and to reach a consensus on nomenclature and clinicopathological significance of ATRT subgroups. Methods We integrated various methods to perform a meta-analysis on published and unpublished DNA methylation and gene expression datasets of ATRTs and associated clinicopathological data. Results In concordance with previous studies, the analyses identified 3 main molecular subgroups of ATRTs, for which a consensus was reached to name them ATRT-TYR, ATRT-SHH, and ATRT-MYC. The ATRT-SHH subgroup exhibited further heterogeneity, segregating further into 2 subtypes associated with a predominant supratentorial (ATRT-SHH-1) or infratentorial (ATRT-SHH-2) location. For each ATRT subgroup we provide an overview of its main molecular and clinical characteristics, including SMARCB1 alterations and pathway activation. Conclusions The introduction of a common classification, characterization, and nomenclature of ATRT subgroups will facilitate future research and serve as a common ground for subgrouping patient samples and ATRT models, which will aid in refining subgroup-based therapies for ATRT patients.

[1]  M. Kool,et al.  Tyrosinase immunohistochemistry can be employed for the diagnosis of atypical teratoid/rhabdoid tumours of the tyrosinase subgroup (ATRT‐TYR) , 2020, Neuropathology and applied neurobiology.

[2]  Steven J. M. Jones,et al.  Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration , 2019, Cell reports.

[3]  Geoffrey M. Nelson,et al.  Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. , 2019, Cell reports.

[4]  Martin Sill,et al.  Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes , 2019, Acta Neuropathologica.

[5]  David T. W. Jones,et al.  Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. , 2019, Cancer cell.

[6]  David T. W. Jones,et al.  A biobank of patient-derived pediatric brain tumor models , 2018, Nature Medicine.

[7]  Martin Sill,et al.  Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.

[8]  M. Kool,et al.  Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid/rhabdoid tumor , 2018, Neuro-oncology.

[9]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[10]  A. Bahrami,et al.  Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous , 2018, Acta Neuropathologica.

[11]  D. Surdez,et al.  High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. , 2017, Cell reports.

[12]  G. Coppola,et al.  Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development , 2017, Nature Communications.

[13]  Sirintra Nakjang,et al.  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study , 2017, The Lancet. Oncology.

[14]  David T. W. Jones,et al.  Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1‐deficient non‐rhabdoid tumor with favorable long‐term outcome , 2017, Brain pathology.

[15]  A. Goldenberg,et al.  Intertumoral Heterogeneity within Medulloblastoma Subgroups. , 2017, Cancer cell.

[16]  K. Aldape,et al.  The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants , 2016, Acta Neuropathologica.

[17]  M. Prados,et al.  Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. , 2016, Neuro-oncology.

[18]  A. Tan,et al.  Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors , 2016, Cell reports.

[19]  Mei Lu,et al.  Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. , 2016, Cancer cell.

[20]  C. Roberts,et al.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. , 2016, Neuro-oncology.

[21]  Roland Eils,et al.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.

[22]  P. Varlet,et al.  The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation , 2016, Nature Communications.

[23]  Zhe Zhang,et al.  Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53. , 2015, Cancer research.

[24]  M. Dreyling,et al.  Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature , 2015, European journal of haematology.

[25]  Gary D Bader,et al.  Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. , 2015, The Lancet. Oncology.

[26]  B. Weissman,et al.  The Chromatin-Modifying Protein HMGA2 Promotes Atypical Teratoid/Rhabdoid Cell Tumorigenicity , 2015, Journal of neuropathology and experimental neurology.

[27]  M. Bronner,et al.  Establishing neural crest identity: a gene regulatory recipe , 2015, Development.

[28]  M. Kool,et al.  Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1 , 2014, International journal of cancer.

[29]  R. Siebert,et al.  SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis , 2014, Acta Neuropathologica.

[30]  Tim J. Wigle,et al.  Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.

[31]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[32]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[33]  B. Kleinschmidt-DeMasters,et al.  High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. , 2011, Neuro-oncology.

[34]  Pablo Tamayo,et al.  Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway , 2010, Nature Medicine.

[35]  R. Siebert,et al.  Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.

[36]  A. Aguzzi,et al.  Tyrosinase is a new marker for cell populations in the mouse neural tube , 1996 .